Race and ethnicity representation in clinical trials: findings from a literature review of Phase I oncology trials

被引：35

作者：

Camidge, D. Ross ^{[1
]}

Park, Haeseong ^{[2
]}

Smoyer, Karen E. ^{[3
]}

Jacobs, Ira ^{[4
]}

Lee, Lauren J. ^{[4
]}

Askerova, Zemfira ^{[4
]}

McGinnis, Justin ^{[5
]}

Zakharia, Yousef ^{[6
]}

机构：

[1] Univ Colorado Hosp, Div Med Oncol, Aurora, CO 80045 USA

[2] Washington Univ, Siteman Canc Ctr, Div Oncol, St Louis, MO 63110 USA

[3] Envis Pharma Grp, Philadelphia, PA 19109 USA

[4] Pfizer Inc, New York, NY 10017 USA

[5] Pfizer Inc, La Jolla, CA 92121 USA

[6] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA

来源：

FUTURE ONCOLOGY | 2021年 / 17卷 / 24期

关键词：

clinical trial; disparities; ethnicity; oncology; Phase I; race; AMERICAN SOCIETY; PROSTATE-CANCER; DISPARITY; STATEMENT; MORTALITY; HEALTH;

D O I：

10.2217/fon-2020-1262

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To provide an assessment of published literature on the demographic representation in Phase I trials of biopharmaceutical oncology agents. Materials & methods: We conducted a rapid evidence assessment to identify demographic representation reported in Phase I clinical trials for biopharmaceutical oncology agents published in 2019. Results: Globally, the population was predominantly White/Caucasian (62.2%). In the USA, the distribution was heavily skewed toward White/Caucasian (84.2%), with minimal representation of Blacks/African-Americans (7.3%), Asians (3.4%), Hispanics/Latinos (2.8%) or other race/ethnicity groups. Conclusion: Our data highlight that Phase I oncology trials do not reflect the population at large, which may perpetuate health disparities. Further research is needed to understand and address barriers to participation, particularly among under-represented groups

引用

页码：3271 / 3280

页数：10

共 36 条

[1] Patients' decision-making process regarding participation in phase I oncology research [J].

Agrawal, Manish ;

Grady, Christine ;

Fairclough, Diane L. ;

Meropol, Neal J. ;

Maynard, Kim ;

Emanuel, Ezekiel J. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) :4479-4484

[2] Disparities in Cancer Care [J].

不详 .

JOURNAL OF ONCOLOGY PRACTICE, 2006, 2 (05) :234-239

[3]

[Anonymous], WORLD FACTBOOK

[4] Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer [J].

Bagley, Alexander F. ;

Anscher, Mitchell S. ;

Choi, Seungtaek ;

Frank, Steven J. ;

Hoffman, Karen E. ;

Kuban, Deborah A. ;

McGuire, Sean E. ;

Quynh-Nhu Nguyen ;

Chapin, Brian ;

Aparicio, Ana ;

Pezzi, Todd A. ;

Smith, Grace L. ;

Smith, Benjamin D. ;

Hess, Kenneth ;

Tang, Chad .

JAMA NETWORK OPEN, 2020, 3 (03)

[5]

Center for Biologics Evaluation and Research Center for Drug Evaluation and Research, 2020, ENH DIV CLIN TRIAL P

[6]

Centre for Reviews and Dissemination University of York, SYSTEMATIC REV CRDS

[7]

Congress.gov, COV LIF SAV INV NEED

[8] Social determinants of breast cancer risk, stage, and survival [J].

Coughlin, Steven S. .

BREAST CANCER RESEARCH AND TREATMENT, 2019, 177 (03) :537-548

[9]

Das H, 2020, UROLOGY, V136, P9, DOI [10.1016/j.urology.2019.09.058, 10.1016/j.urology.2019.09.058Get]

[10] A Qualitative Study Exploring Barriers and Facilitators of Enrolling Underrepresented Populations in Clinical Trials and Biobanking [J].

Davis, Terry C. ;

Arnold, Connie L. ;

Mills, Glenn ;

Miele, Lucio .

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2019, 7

← 1 2 3 4 →